Evidence map›Paper›PMID 36182721›Full record

ArticleSeminars in arthritis and rheumatism2022

Sarcoidosis incidence after mTOR inhibitor treatment.

Matthew C Baker, Emese Vágó, Yuhan Liu, Rong Lu, Suzanne Tamang, Erzsébet Horváth-Puhó, Henrik Toft Sørensen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Seminars in arthritis and rheumatism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple Systems.Journal of cardiovascular translational research · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew C BakerThe Division of Immunology and Rheumatology, Department of Medicine, Stanford University,1000 Welch Rd, Suite 203, Palo Alto, Stanford, CA 94304, USA. Electronic address: mbake13@stanford.edu.
Emese VágóThe Department of Clinical Epidemiology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Yuhan LiuThe Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA, USA.
Rong LuThe Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA, USA.
Suzanne TamangThe Division of Immunology and Rheumatology, Department of Medicine, Stanford University,1000 Welch Rd, Suite 203, Palo Alto, Stanford, CA 94304, USA.
Erzsébet Horváth-PuhóThe Department of Clinical Epidemiology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Henrik Toft SørensenThe Department of Clinical Epidemiology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; The Clinical Excellence Science Center, Stanford University, Stanford, CA, USA.

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Stanford TRANSFORM I2T ProgramR25AI147369 · NIAID · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW, SINGH, UPINDER · 2019 to 2023
$1.8M
NCATS NIH HHS UL1 TR003142NIAID NIH HHS R25 AI147369
6 · The paper itself

Abstract

objectiveMechanistic target of rapamycin (mTOR) inhibitors are effective in animal models of granulomatous disease, but their benefit in sarcoidosis patients is unknown. We evaluated the incidence of sarcoidosis in patients treated with mTOR inhibitors versus calcineurin inhibitors.

methodsThis was a cohort study using the Optum Clinformatics® Data Mart (CDM) Database (2003-2019), IBM® MarketScan® Research Database (2006-2016), and Danish health and administrative registries (1996-2018). Patients aged ≥18 years with ≥1 year continuous enrollment before and after kidney, liver, heart, or lung transplant treated with an mTOR inhibitor or calcineurin inhibitor were included. Patients diagnosed with sarcoidosis before, or up to 90 days after, transplant were excluded. The incidence of sarcoidosis by treatment group was calculated.

resultsIn the Optum CDM/IBM MarketScan cohort, 1,898 patients were treated with an mTOR inhibitor (mean age 49 years; 34% female) and 9,894 patients were treated with a calcineurin inhibitor (mean age 50 years; 37% female). The mean follow-up in the mTOR inhibitor group was 1.1 years, with no incident sarcoidosis diagnosed. In the calcineurin inhibitor group, the mean follow-up was 2.2 years, with 12 incident sarcoidosis cases diagnosed. In the Danish cohort, 230 patients were treated with an mTOR inhibitor (mean age 49; 45% female), with no incident sarcoidosis diagnosed. There were 3,411 patients treated with a calcineurin inhibitor (mean age 45; 40% female), with 10 incident cases of sarcoidosis diagnosed.

conclusionsThis study indicates a potential protective effect of mTOR inhibitor treatment compared with calcineurin inhibitor treatment against the development of sarcoidosis.

Indexed as

Immunosuppressive AgentsKidney TransplantationMTOR InhibitorsSarcoidosisCalcineurin InhibitorsCohort StudiesFemaleHumansIncidenceMaleTOR Serine-Threonine KinasesCalcineurin InhibitorsImmunosuppressive AgentsMTOR InhibitorsMTOR protein, humanTOR Serine-Threonine KinasesGranulomamTORSarcoidosis

Identifiers

PMID36182721
PMCPMC10321418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.